List of nationally authorised medicinal products
|
|
- Candace Norman
- 6 years ago
- Views:
Transcription
1 26 October 2017 EMA/663700/2017 Human Medicines Evaluation Division Active substance: cromoglicic acid Procedure no.: PSUSA/ / Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.
2 Alleofta 20 mg/ml kapi za oko, otopina u jednodoznom spremniku Alleofta 20 mg/ml kapi za oko, otopina u jednodoznom spremniku Alleophta 20 mg/ml, očná roztoková instilácia v jednodávkovom obale Alleophta 20 mg/ml, očná roztoková instilácia v jednodávkovom obale UK/H/5451/001 HR-H SANOFI-AVENTIS CROATIA D.O.O. UK/H/5451/001 HR-H SANOFI-AVENTIS CROATIA D.O.O. UK/H/5451/001 64/0414/16-S SANOFI-AVENTIS SLOVAKIA SRO UK/H/5451/001 64/0414/16-S SANOFI-AVENTIS SLOVAKIA SRO HR HR SK SK Alleophta unidosis 20 mg/ml, collyre en solution en récipient unidose Alleophta unidosis 20 mg/ml, collyre en solution en récipient unidose Alleophta unidosis 20 mg/ml, collyre en solution en récipient unidose Alleophta unidosis 20 mg/ml, collyre en solution en récipient unidose UK/H/5451/01/DC BE SANOFI BELGIUM BE UK/H/5451/01/DC BE SANOFI BELGIUM BE UK/H/5451/01/DC SANOFI BELGIUM LU UK/H/5451/01/DC SANOFI BELGIUM LU EMA/663700/2017 Page 2/26
3 Alleophta unidosis 20 mg/ml, oogdruppels, oplossing in verpakking voor éénmalig gebruik Alleophta unidosis 20 mg/ml, oogdruppels, oplossing in verpakking voor éénmalig gebruik Alleopti 20 mg/ ml oldatos szemcsepp ALLEOPTI 20 MG/ML OLDATOS SZEMCSEPP Alleopti Komfort 20 mg/ ml oldatos szemcsepp egyadagos tartályban Alleopti Komfort 20 mg/ ml oldatos szemcsepp egyadagos tartályban Alleoptical, 20 mg/ml, krople do oczu, roztwór w pojemniku jednodawkowym Alleoptical, 20 mg/ml, krople do oczu, roztwór w pojemniku jednodawkowym UK/H/5451/01/DC BE SANOFI BELGIUM BE UK/H/5451/01/DC BE SANOFI BELGIUM BE not available OGYI-T-22584/01 SANOFI-AVENTIS ZRT HU not available OGYI-T-22584/04 SANOFI-AVENTIS ZRT HU not available OGYI-T-22584/03 SANOFI-AVENTIS ZRT HU not available OGYI-T-22584/02 SANOFI-AVENTIS ZRT HU UK/H/5451/01/DC AVENTIS PHARMA LTD PL UK/H/5451/01/DC AVENTIS PHARMA LTD PL EMA/663700/2017 Page 3/26
4 Allerg-Abak 20 mg/ml oogdruppels, oplossing FR/H/0234/001 RVG LABORATOIRES THEA NL Allergo-COMOD eye drops not available MA063/00201 URSAPHARM ARZNEIMITTEL GMBH MT Allergo-COMOD neusspray not available RVG URSAPHARM BENELUX B.V. NL Allergo-COMOD ocní kapky, Oční kapky, roztok not available 64/020/01-C URSAPHARM SPOL. S.R.O. CZ Allergo-COMOD oogdruppels not available RVG URSAPHARM BENELUX B.V. NL Allergo-COMOD, 20 mg/ml, krople do oczu, roztwór ALLERGOCOMOD, collyre en solution not available 9762 URSAPHARM POLAND SP. Z. O.O. not available LABORATOIRES URSAPHARM S.A.S. PL FR Allergo-COMOD Augentropfen Allergo-COMOD Nasenspray not available URSAPHARM GES.M.B.H. AT not available URSAPHARM GES.M.B.H. AT Allergocrom not available 64/0662/94-S URSAPHARM ARZNEIMITTEL GMBH SK Allergocrom nosní sprej, Nosní sprej, roztok Allergocrom oční kapky, roztok not available 69/945/97-C URSAPHARM SPOL. S.R.O. CZ not available 64/072/97-C URSAPHARM SPOL. S.R.O. CZ EMA/663700/2017 Page 4/26
5 Allergocrom, 20 mg/ml, krople do oczu, roztwór not available 8980 URSAPHARM POLAND SP. Z. O.O. PL Allergoval Kapseln not available KOEHLER PHARMA GMBH Allgil 20 mg/ml ögondroppar, lösning Aspire Allergy Relief 2% w/v eye drops, Solution (eye drops) Aspire Hayfever Relief 2% w/v Eye Drops Boots Allergy Relief 2% w/v Eye Drops Boots Hayfever Relief 2% w/v Eye Drops Catacrom 2% w/v eye drops, solution not available APOFRI AB SE not available PL 35533/0033 ASPIRE PHARMA LIMITED UK not available PL 35533/0031 ASPIRE PHARMA LIMITED UK not available PL03468/0023 BAUSCH & LOMB UK LTD. UK not available PL 35533/0031 ASPIRE PHARMA LIMITED UK UK/H/1718/001 PA 1464/1/1 RAYNER PHARMACEUTICALS IE Catacrom 2% w/v eye drops, solution COLIMUNE SACHETS 100 MG COLIMUNE SACHETS 100 MG UK/H/1718/001 PL11412/0002 MOORFIELDS EYE HOSPITAL NHS FOUNDATION TRUST not available SANOFI-AVENTIS UTSCHLAND GMBH not available SANOFI-AVENTIS UTSCHLAND GMBH UK EMA/663700/2017 Page 5/26
6 COLIMUNE SACHETS 100 MG COLIMUNE SACHETS 200 MG COLIMUNE SACHETS 200 MG COLIMUNE SACHETS 200 MG not available SANOFI-AVENTIS UTSCHLAND GMBH not available SANOFI-AVENTIS UTSCHLAND GMBH not available SANOFI-AVENTIS UTSCHLAND GMBH not available SANOFI-AVENTIS UTSCHLAND GMBH CROMABAK 20 mg/ml colirio en solución CROMABAK 20 mg/ml collirio soluzione Cromabak 20 mg/ml collyre en solution Cromabak 20 mg/ml collyre en solution Cromabak 20 mg/ml oogdruppels, oplossing Cromabak 20 mg/ml, colírio, solução Cromabak 20 mg/ml, colírio, solução FR/H/0234/ LABORATOIRES THEA ES FR/H/0234/ LABORATOIRES THEA IT not available BE THEA PHARMA BE not available BE THEA PHARMA LU not available BE THEA PHARMA BE not available LABORATOIRES THEA PT not available LABORATOIRES THEA PT EMA/663700/2017 Page 6/26
7 CROMABAK 20 mg/ml, collyre en solution Crominet 20 mg/ml ögondroppar, lösning Crominet 20 mg/ml øyedråper, oppløsning Crominet, øjendråber, opløsning CROMOFREE 2 %, collyre en solution Cromoglicato de Sodio Brown 20 mglml colirio, solucao Cromoglicato de Sodio Brown 20 mglml colirio, solucao FR/H/0234/ LABORATOIRES THEA FR SE/H/1372/ ORIFARM GENERICS A/S SE SE/H/1372/ ORIFARM GENERICS A/S NO SE/H/1372/ ORIFARM GENERICS A/S DK not available LABORATOIRE CHAUVIN FR UK/H/3500/ BROWN & BURK UK LIMITED PT UK/H/3500/ BROWN & BURK UK LIMITED PT CROMOHEXAL not available 64/142/96-C LABORATOIRES THEA CZ CROMOHEXAL 20 mg/1 ml Nosní sprej, roztok not available 24/141/96-C HEXAL AG CZ Cromolux 2% Eye Drops not available PL 03468/0022 BAUSCH & LOMB UK LTD. UK Cromolux 2% Hay fever Eye Drops not available PL03468/0023 BAUSCH & LOMB UK LTD. UK EMA/663700/2017 Page 7/26
8 Crom-Ophtal 1 ml Augentropfen enthält 20 mg Natriumcromoglicat (Ph.Eur.) not available DR. WINZER PHARMA GMBH Crom-Ophtal Nasenspray not available DR. WINZER PHARMA GMBH Crom-Ophtal sine 1 ml Augentropfen enthält 20 mg Natriumcromoglicat (Ph.Eur.) CROMOPTIC 2 %, collyre en solution CROMOPTIC 2 %, collyre en solution en récipient unidose not available DR. WINZER PHARMA GMBH not available LABORATOIRE CHAUVIN FR not available LABORATOIRE CHAUVIN FR CUSICROM FUERTE OFTÁLMICO 40 mg/ml colirio en solución not available NOVARTIS FARMACÉUTICA S.A. ES EM Pharma Allergy Relief 2%w/v Eye Drops, Solution (eye drops) EM Pharma Hayfever Relief 2%w/v Eye Drops not available PL 35533/0033 ASPIRE PHARMA LIMITED UK not available PL 35533/0031 ASPIRE PHARMA LIMITED UK Fenolip 20 mg/ml solução para inalação por nebulização not available ANGELINI FARMACÊUTICA, LDA PT EMA/663700/2017 Page 8/26
9 Fenolip, 10 mg / 0,5 ml, colírio, solução Fenolip, 20 mg/ml, colírio, solução not available ANGELINI FARMACÊUTICA, LDA not available ANGELINI FARMACÊUTICA, LDA PT PT INTAL CFC-FREE INHALER not available PL 04425/0179 AVENTIS PHARMA LTD UK INTAL INHALATIONLÖSUNG 1% INTAL INHALATIONLÖSUNG 1% INTAL INHALATIONLÖSUNG 1% INTAL INHALATIONLÖSUNG 1% not available SANOFI-AVENTIS UTSCHLAND GMBH not available SANOFI-AVENTIS UTSCHLAND GMBH not available SANOFI-AVENTIS UTSCHLAND GMBH not available SANOFI-AVENTIS UTSCHLAND GMBH INTAL N AEROSOL not available SANOFI-AVENTIS UTSCHLAND GMBH INTAL N AEROSOL not available SANOFI-AVENTIS UTSCHLAND GMBH INTAL N AEROSOL not available SANOFI-AVENTIS UTSCHLAND GMBH INTAL N AEROSOL not available SANOFI-AVENTIS UTSCHLAND GMBH EMA/663700/2017 Page 9/26
10 INTAL N AEROSOL not available SANOFI-AVENTIS UTSCHLAND GMBH INTAL N AEROSOL not available SANOFI-AVENTIS UTSCHLAND GMBH INTAL N AEROSOL not available SANOFI-AVENTIS UTSCHLAND GMBH Lecrolyn not available SANTEN OY DK LECROLYN 20 mg/ml acu pilieni, šķīdums LECROLYN 20 mg/ml akių lašai (tirpalas) Lecrolyn 20 mg/ml ögondroppar, lösning, endosbehållare LECROLYN 20 mg/ml silmatilgad, lahus LECROLYN 20 mg/ml - silmätipat, liuos LECROLYN 40 mg/ml acu pilieni, šķīdums LECROLYN 40 mg/ml akių lašai (tirpalas) not available SANTEN OY LV not available LT/1/96/2408/001 SANTEN OY LT not available SANTEN OY SE not available SANTEN OY EE not available SANTEN OY FI not available SANTEN OY LV not available LT/1/96/2408/002 SANTEN OY LT EMA/663700/2017 Page 10/26
11 LECROLYN 40 mg/ml akių lašai, tirpalas LECROLYN 40 mg/ml akių lašai, tirpalas Lecrolyn 40 mg/ml ögondroppar, lösning Lecrolyn 40 mg/ml ögondroppar, lösning, endosbehållare Lecrolyn 40 mg/ml øyedråper, oppløsning i dråpeflaske Lecrolyn 40 mg/ml øyedråper, oppløsning i endosebeholdere LECROLYN 40 mg/ml silmatilgad, lahus LECROLYN 40 mg/ml - silmätipat, liuos Lecrolyn sine 40 mg/ml akių lašai (tirpalas) Lecrolyn sine 40 mg/ml akių lašai (tirpalas) not available LT/1/96/2408/004 SANTEN OY LT not available LT/1/96/2408/005 SANTEN OY LT not available SANTEN OY SE not available SANTEN OY SE not available 8306 SANTEN OY NO not available SANTEN OY NO not available SANTEN OY EE not available SANTEN OY FI SE/H/1402/001 LT/1/15/3711/001 SANTEN OY LT SE/H/1402/001 LT/1/15/3711/002 SANTEN OY LT EMA/663700/2017 Page 11/26
12 Lecrolyn sine 40 mg/ml akių lašai (tirpalas) Lecrolyn sine 40 mg/ml augndropar, lausn Lecrolyn sine 40 mg/ml ögondroppar, lösning Lecrolyn sine 40 mg/ml ögondroppar, lösning Lecrolyn sine 40 mg/ml øyedråper, oppløsning Lecrolyn sine 40 mg/ml silmatilgad, lahus Lecrolyn sine 40 mg/ml silmätipat, liuos Lecrolyn sine, øjendråber, opløsning Lecrolyn, øjendråber, opløsning LECROLYN 20 mg/ml ögondroppar, lösning LECROLYN 20 mg/ml ögondroppar, lösning i endosbehållare SE/H/1402/001 LT/1/15/3711/003 SANTEN OY LT SE/H/1402/01/DC IS/1/15/035/01 SANTEN OY IS SE/H/1402/ SANTEN OY FI SE/H/1402/ SANTEN OY SE SE/H/1402/01/DC SANTEN OY NO SE/H/1402/ SANTEN OY EE SE/H/1402/01/DC SANTEN OY FI SE/H/1402/ SANTEN OY DK not available SANTEN OY DK not available SANTEN OY FI not available SANTEN OY FI EMA/663700/2017 Page 12/26
13 LECROLYN 20 mg/ml - silmätipat, liuos kertaannospakkauksessa LECROLYN 40 mg/ml ögondroppar, lösning LECROLYN 40 mg/ml ögondroppar, lösning i endosbehållare LECROLYN 40 mg/ml - silmätipat, liuos kertaannospakkauksessa not available SANTEN OY FI not available SANTEN OY FI not available SANTEN OY FI not available SANTEN OY FI LOMUDAL not available MT SANOFI-AVENTIS NMARK A/S DK LOMUDAL not available SANOFI SPA IT LOMUDAL not available 8593 SANOFI AB SE LOMUDAL 20 MG not available RVG SANOFI-AVENTIS NETHERLANDS B.V. LOMUDAL 20 MG not available RVG SANOFI-AVENTIS NETHERLANDS B.V. NL NL Lomudal 20 mg inhalationspulver, hård kapsel not available 8593 SANOFI AB SE EMA/663700/2017 Page 13/26
14 Lomudal 20 mg inhalationspulver, hård kapsel LOMUDAL 20 mg, solution pour inhalation par nébuliseur Lomudal 20 mg, verneveloplossing Lomudal 20 mg/ml ögondroppar, lösning Lomudal 20 mg/ml ögondroppar, lösning Lomudal 20 mg/ml øyedråper, oppløsning Lomudal 20 mg/ml øyedråper, oppløsning Lomudal 20 mg/ml øyedråper, oppløsning LOMUDAL 20 MG/ML SILMATIPAT, LIUOS LOMUDAL 20 MG/ML SILMATIPAT, LIUOS not available 8593 SANOFI AB SE not available BE SANOFI BELGIUM BE not available BE SANOFI BELGIUM BE not available 9326 SANOFI AB SE not available 9326 SANOFI AB SE not available 6300 SANOFI-AVENTIS NORGE AS NO not available 6300 SANOFI-AVENTIS NORGE AS NO not available 6300 SANOFI-AVENTIS NORGE AS NO not available 7589 SANOFI OY FI not available 7589 SANOFI OY FI EMA/663700/2017 Page 14/26
15 Lomudal 20 mg/ml, augndropar, lausn Lomudal 40 mg/ml ögondroppar, lösning, endosbehållare Lomudal 40 mg/ml ögondroppar, lösning, endosbehållare Lomudal 40 mg/ml øyedråper, oppløsning i endosebeholder Lomudal 40 mg/ml øyedråper, oppløsning i endosebeholder LOMUDAL 40 MG/ML SILMATIPAT, LIUOS KERTA- ANNOSPIPETISSA LOMUDAL 40 MG/ML SILMATIPAT, LIUOS KERTA- ANNOSPIPETISSA LOMUDAL 40mg/ml collirio, soluzione LOMUDAL 40mg/ml spray nasale, soluzione not available SANOFI-AVENTIS NORGE AS IS not available SANOFI AB SE not available SANOFI AB SE not available 7842 SANOFI-AVENTIS NORGE AS NO not available 7842 SANOFI-AVENTIS NORGE AS NO not available SANOFI OY FI not available SANOFI OY FI not available SANOFI SPA IT not available SANOFI SPA IT EMA/663700/2017 Page 15/26
16 LOMUDAL FORTE not available RVG SANOFI-AVENTIS NETHERLANDS B.V. NL LOMUDAL FREONITON 5 MG/ANNOS INHALAATIOSUMUTE, SUSPENSIO not available SANOFI OY FI LOMUDAL G.I. not available SANOFI AB SE LOMUDAL G.I. not available SANOFI AB SE LOMUDAL NASAL not available SANOFI-AVENTIS NMARK A/S DK LOMUDAL NASAL not available SANOFI AB SE LOMUDAL NASAL not available SANOFI AB SE LOMUDAL NASAL 5,2 MG/ANNOS NENASUMUTE, LIUOS LOMUDAL NASAL 5,2 MG/ANNOS NENASUMUTE, LIUOS Lomudal Nasal 5,2 mg/dose nesespray, oppløsning Lomudal Nasal 5,2 mg/dose nesespray, oppløsning not available SANOFI OY FI not available SANOFI OY FI not available 00/7496 SANOFI-AVENTIS NORGE AS NO not available 00/7496 SANOFI-AVENTIS NORGE AS NO EMA/663700/2017 Page 16/26
17 LOMUDAL NEBULISER SOL. FOR INH. (GLASS VIALS) not available SANOFI BELGIUM LU Lomudal, øjendråber, opløsning Lomudal, øjendråber, opløsning Lomudal, øjendråber, opløsning, enkeltdosisbeholder Lomudal, øjendråber, opløsning, enkeltdosisbeholder not available SANOFI-AVENTIS NMARK A/S not available SANOFI-AVENTIS NMARK A/S not available SANOFI-AVENTIS NMARK A/S not available SANOFI-AVENTIS NMARK A/S DK DK DK DK LOMUDAL, SOLUTION POUR NEBULISATION LOMUDAL, SOLUTION POUR NEBULISATION Lomudal Gastrointestinum 100 mg kapselit not available SANOFI-AVENTIS FRANCE FR not available SANOFI-AVENTIS FRANCE FR not available 8299 ITALCHIMICI S.P.A. FI LOMUSOL 2% not available 0006/ SANOFI BELGIUM LU Lomusol 2% neusdruppels, oplossing Lomusol 2% solution pour instillation nasale not available BE SANOFI BELGIUM BE not available BE SANOFI BELGIUM BE EMA/663700/2017 Page 17/26
18 LOMUSOL 4 POUR CENT, solution pour pulvérisation nasale LOMUSOL 4 POUR CENT, solution pour pulvérisation nasale Lomusol 4% neusspray, oplossing Lomusol 4% solution pour pulvérisation nasale not available SANOFI-AVENTIS FRANCE FR not available SANOFI-AVENTIS FRANCE FR not available BE SANOFI BELGIUM BE not available BE SANOFI BELGIUM BE LOMUSOL 4% SPRAY not available SANOFI BELGIUM LU MULTICROM 2 %, collyre en solution MULTICROM UNIDOSES 2 POUR CENT, collyre en récipient unidose MULTICROM UNIDOSES 2 POUR CENT, collyre en récipient unidose MULTICROM UNIDOSES 2 POUR CENT, collyre en récipient unidose not available LABORATOIRES THEA FR not available LABORATOIRES THEA FR not available LABORATOIRES THEA FR not available LABORATOIRES THEA FR EMA/663700/2017 Page 18/26
19 MULTICROM UNIDOSES 2 POUR CENT, collyre en récipient unidose not available LABORATOIRES THEA FR NALCROM not available RVG SANOFI-AVENTIS NETHERLANDS B.V. NALCROM not available RVG SANOFI-AVENTIS NETHERLANDS B.V. NL NL NALCROM not available 14/0305/89-S ITALCHIMICI S.P.A. SK Nalcrom 100 mg capsule rigide Nalcrom 100 mg, tvrdé tobolky not available ITALCHIMICI S.P.A. IT not available 14/305/89-S/C ITALCHIMICI S.P.A. CZ NALCROM 100MG CAPSULES not available PL 04425/0370 AVENTIS PHARMA LTD UK Nalcrom 250 mg granulato per soluzione orale NALCROM 250 mg granulato per soluzione orale Nalcrom 500 mg granulato per soluzione orale NALCROM 500 mg granulato per soluzione orale not available ITALCHIMICI S.P.A. IT not available ITALCHIMICI S.P.A. IT not available ITALCHIMICI S.P.A. IT not available ITALCHIMICI S.P.A. IT EMA/663700/2017 Page 19/26
20 NALCROM DRANK 100 MG not available RVG SANOFI-AVENTIS NETHERLANDS B.V. NALCROM DRANK 200 MG not available RVG SANOFI-AVENTIS NETHERLANDS B.V. NL NL Natriumcromoglicaat Apotex 20 mg/ml not available RVG APOTEX EUROPE B.V. NL NATRIUMCROMOGLICAAT OOGDRUPPELS 20 G/ML not available RVG BASIC PHARMA MANUFACTURING BV NL Natriumkromoglikat ABECE 20 mg/ml ögondroppar, lösning Numark Hayfever Relief 2% w/v Eye Drops OPHTACALM 2 %, collyre en solution en récipient unidose OPHTACALM 2 %, collyre en solution en récipient unidose OPHTACALM 2 %, collyre en solution en récipient unidose OPHTACALMFREE 2%, collyre en solution not available EVOLAN PHARMA AB SE not available PL 35533/0031 ASPIRE PHARMA LIMITED UK not available LABORATOIRE CHAUVIN FR not available LABORATOIRE CHAUVIN FR not available LABORATOIRE CHAUVIN FR not available LABORATOIRE CHAUVIN FR OPTICROM not available RVG SANOFI-AVENTIS NETHERLANDS B.V. NL EMA/663700/2017 Page 20/26
21 OPTICROM 2 % collyre en solution OPTICROM 2 % collyre en solution OPTICROM 2 % oogdruppels, oplossing Natrium cromoglicaat not available BE MELISANA NV BE not available MELISANA NV LU not available BE MELISANA NV BE Opticrom 2% Augentropfen not available BE MELISANA NV BE Opticrom 2% Augentropfen not available MELISANA NV LU Opticrom 20 mg/ ml oldatos szemcsepp Opticrom 20 mg/ml colirio en solución en envase unidosis Opticrom 20 mg/ml colirio en solución en envase unidosis not available OGYI-T-3691/02 SANOFI-AVENTIS ZRT HU UK/H/5451/01/DC SANOFI-AVENTIS, S.A. ES UK/H/5451/01/DC SANOFI-AVENTIS, S.A. ES Opticrom 20 mg/ml Colírio, solução em frasco contagotas multidose Opticrom 20mg/ml Colírio, Solução em Unidose not available SANOFI - PRODUTOS FARMACEUTICOS LDA not available SANOFI - PRODUTOS FARMACEUTICOS LDA PT PT EMA/663700/2017 Page 21/26
22 Opticrom 20mg/ml Colírio, Solução em Unidose Opticrom Allergy 2%w/v Eye Drops, solution Opticrom Allergy 2%w/v Eye Drops, solution Opticrom Allergy 2%w/v Eye Drops, solution not available SANOFI - PRODUTOS FARMACEUTICOS LDA not available PA 540/116/2 SANOFI-AVENTIS IRELAND LTD not available PA 540/116/2 SANOFI-AVENTIS IRELAND LTD not available PA 540/116/2 SANOFI-AVENTIS IRELAND LTD PT IE IE IE OPTICROM ALLERGY 2.0% W/W EYE DROPS, SOLUTION OPTICROM ALLERGY 2.0% W/W EYE DROPS, SOLUTION not available PL 04425/0323 AVENTIS PHARMA LTD UK not available PL 04425/0323 AVENTIS PHARMA LTD UK Opticrom Allergy Single Dose 2% w/v Eye Drops, Solution Opticrom Allergy Single Dose 2% w/v Eye Drops, Solution UK/H/5451/01/DC PA 540/116/3 SANOFI-AVENTIS IRELAND LTD UK/H/5451/01/DC PA 540/116/3 SANOFI-AVENTIS IRELAND LTD IE IE Opticrom Allergy Single Dose 2% w/v Eye Drops, Solution UK/H/5451/01/DC PL 04425/0688 AVENTIS PHARMA LTD UK EMA/663700/2017 Page 22/26
23 Opticrom Allergy Single Dose 2% w/v Eye Drops, Solution OPTICROM AQUEOUS / VISICROM EYE DROPS OPTICROM AQUEOUS / VISICROM EYE DROPS UK/H/5451/01/DC PL 04425/0688 AVENTIS PHARMA LTD UK not available PL 04425/0324 AVENTIS PHARMA LTD UK not available PL 04425/0324 AVENTIS PHARMA LTD UK OPTICROM EYE DROPS not available PA 540/116/1 SANOFI-AVENTIS IRELAND LTD OPTICROM EYE DROPS not available PA 540/116/1 SANOFI-AVENTIS IRELAND LTD OPTICROM EYE DROPS not available PA 540/116/1 SANOFI-AVENTIS IRELAND LTD IE IE IE OPTICROM HAYFEVER 2% W/V EYE DROPS OPTICROM HAYFEVER 2% W/V EYE DROPS OPTICROM OLDATOS SZEMCSEPP not available PL 04425/0628 AVENTIS PHARMA LTD UK not available PL 04425/0628 AVENTIS PHARMA LTD UK not available OGYI-T-3691/01 SANOFI-AVENTIS ZRT HU OPTICROM UNIT DOSE not available RVG SANOFI-AVENTIS NETHERLANDS B.V. NL OpticromTM Allergy 2.0% w/v Eye Drops, Solution not available MA 082/01901 SANOFI MALTA LTD MT EMA/663700/2017 Page 23/26
24 OpticromTM Allergy 2.0% w/v Eye Drops, Solution not available MA 082/01901 SANOFI MALTA LTD MT OPTICRON 2 POUR CENT, collyre OPTICRON UNIDOSE, collyre en récipient unidose not available COOPERATION PHARMACEUTIQUE FRANCAISE not available COOPERATION PHARMACEUTIQUE FRANCAISE FR FR Optrex Allergy 2%w/v Eye Drops, Solution (eye drops) Optrex Allergy Eye Drops (sodium cromoglicate 2%) Optrex Hayfever Relief 2%w/v Eye Drops Pollenase Hayfever Relief 2%w/v Eye Drops SODIO CROMOGLICATO SANOFI SODIO CROMOGLICATO SANOFI Sodium Cromoglicate 2% w/v Eye Drops, Solution not available PL 35533/0033 ASPIRE PHARMA LIMITED UK not available PL03468/0023 BAUSCH & LOMB UK LTD. UK not available PL 35533/0031 ASPIRE PHARMA LIMITED UK not available PL 35533/0031 ASPIRE PHARMA LIMITED UK UK/H/5451/01/DC SANOFI SPA IT UK/H/5451/01/DC SANOFI SPA IT not available PL 35533/0032 ASPIRE PHARMA LIMITED UK EMA/663700/2017 Page 24/26
25 Sodium Cromoglicate 2% w/v Eye Drops, Solution Sodium Cromoglicate 2% w/v Eye Drops, Solution Tesco Allergy Eye Drops sodium cromoglicate 2% UK/H/3500/001 PL 25298/0033 BROWN & BURK UK LIMITED UK UK/H/3500/001 PL 25298/0033 BROWN & BURK UK LIMITED UK not available PL03468/0023 BAUSCH & LOMB UK LTD. UK Vivicrom Eye Drops not available PL 03468/0035 BAUSCH & LOMB UK LTD. UK VIVIDRIN not available 75843/ PHARMASWISS ČESKÁ REPUBLIKA S.R.O. VIVIDRIN not available 75843/ PHARMASWISS ČESKÁ REPUBLIKA S.R.O. Vividrin 2% eye drops not available DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH GR GR CY Vividrin Antiallergic Eye Drops, Solution 2%w/v not available PA 555/5/2 BAUSCH & LOMB UK LTD. IE Vividrin Eye Drops not available PL 03468/0035 BAUSCH & LOMB UK LTD. UK Vividrin Hay Fever Eye Drops Vividrin Preservative Free SDU 2% w/v Eye Drops solution not available PL 03468/0035 BAUSCH & LOMB UK LTD. UK not available PA 555/5/3 BAUSCH & LOMB UK LTD. IE EMA/663700/2017 Page 25/26
26 Vividrin antiallergische Augentropfen Vividrin antiallergische Augentropfen Vividrin iso EDO antiallergische Augentropfen not available DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH not available DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH not available DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH LU Vividrin MDO not available DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH Vividrin Nasenspray gegen Heuschnupfen Vividrin Nasenspray gegen Heuschnupfen not available DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH not available DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH LU EMA/663700/2017 Page 26/26
List of nationally authorised medicinal products
09 June 2017 EMA/36849/2017 Human Medicines Evaluation Division Active substance(s): brimonidine / timolol Procedure No.: PSUSA/00000431/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
12 July 2018 EMA/497430/2018 Human Medicines Evaluation Division Active substance: tafluprost / timolol Procedure no.: PSUSA/00010324/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
6 September 2018 EMA/612350/2018 Human Medicines Evaluation Division Active substance: azelastine Procedure no.: PSUSA/00000277/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
5 May 2017 EMA/288255/2017 Human Medicines Evaluation Division Active substance: pilocarpine (ophthalmic formulation) Procedure no.: PSUSA/00002410/201608 30 Churchill Place Canary Wharf London E14 5EU
More informationList of nationally authorised medicinal products
10 September 2015 EMA/622830/2015 Procedure Management and Committees Support Active substance: azelastine Procedure no.: PSUSA/00000277/201412 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
6 September 2018 EMA/615391/2018 Human Medicines Evaluation Division Active substance: tobramycin (nebuliser solution) (apart from centrally authorised product) Procedure no.: PSUSA/00009316/201712 30
More informationList of nationally authorised medicinal products
8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf
More informationList of nationally authorised medicinal products
1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
10 September 2015 EMA/677092/2015 Procedure Management and Committees Support Active substance: glatiramer Procedure no.: PSUSA/00001529/201411 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30
More informationList of nationally authorised medicinal products
10 September 2015 EMA/612853/2015 Procedure Management and Committees Support Active substance: tobramycin (nebuliser solution) Procedure no.: PSUSA/00009316/201412 30 Churchill Place Canary Wharf London
More informationList of nationally authorised medicinal products
30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/00001798/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
28 September 2017 EMA/658449/2017 Human Medicines Evaluation Division Active substance: olodaterol Procedure no.: PSUSA/00010245/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
20 July 2016 EMA/270645/2015 Procedure Management and Committees Support Active substance: apomorphine Procedure no.: PSUSA/00000227/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
11 September 2017 EMA/604559/2017 Human Medicines Evaluation Division Active substance: iron / parenteral preparations Procedure no.: PSUSA/00010236/201701 30 Churchill Place Canary Wharf London E14 5EU
More informationList of nationally authorised medicinal products
30 November 2017 EMA/812360/2017 Human Medicines Evaluation Division Active substance(s): mupirocin Procedure No.: PSUSA/00002096/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
13 September 2017 EMA/706786/2017 Human Medicines Evaluation Division Active substance: Octenidine dihydrochloride / phenoxyethanol Procedure no.: PSUSA/00002199/201701 30 Churchill Place Canary Wharf
More informationList of nationally authorised medicinal products
5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
26 October 2017 EMA/690754/2017 Human Medicines Evaluation Division Active substance: fish oil / olive oil / soybean oil / triglycerides mediumchain Procedure no.: PSUSA/00010223/201702 30 Churchill Place
More informationList of nationally authorised medicinal products
30 November 2017 EMA/795271/2017 Human Medicines Evaluation Division Active substance: vinorelbine Procedure no.: PSUSA/00003124/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605
More informationList of nationally authorised medicinal products
11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill
More informationList of nationally authorised medicinal products
29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
30 November 2017 EMA/817351/2017 Human Medicines Evaluation Division Active substance: Lidocaine / prilocaine (not centrally authorised product) Procedure no.: PSUSA/00001867/201703 30 Churchill Place
More informationList of nationally authorised medicinal products
21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
14 April 2016 EMA/284169/2016 Procedure Management and Committees Support Active substance: influenza vaccine (split virion, inactivated) (non centrally products) Procedure no.: PSUSA/00010298/201508 30
More informationList of nationally authorised medicinal products
29 November 2018 EMA/880324/2018 Human Medicines Evaluation Division Active substance: enalapril Procedure no.: PSUSA/00001211/201803 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/00000435/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile
More informationList of nationally authorised medicinal products
6 September 2018 EMA/608492/2018 Human Medicines Evaluation Division Active substance: betahistine Procedure no.: PSUSA/00000389/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
12 April 2018 EMA/227889/2018 Human Medicines Evaluation Division Active substance(s): typhoid polysaccharide vaccine Procedure No.: PSUSA/00003065/201708 30 Churchill Place Canary Wharf London E14 5EU
More informationList of nationally authorised medicinal products
11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
11 October 2017 EMA/691535/2017 Human Medicines Evaluation Division Active substance: Haemophilus type b conjugate vaccines Procedure no.: PSUSA/00001584/201702 30 Churchill Place Canary Wharf London E14
More informationList of nationally authorised medicinal products
12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United
More informationList of nationally authorised medicinal products
27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill
More informationList of nationally authorised medicinal products
6 September 2018 EMA/619619/2018 Human Medicines Evaluation Division Active substance: haemophilus influenzae / klebsiella ozaenae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus
More informationList of nationally authorised medicinal products
06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20
More informationList of nationally authorised medicinal products
7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationPackage leaflet: Information for the user. Relestat, 0.5 mg/ml, eye drops, solution Epinastine hydrochloride
Package leaflet: Information for the user Relestat, 0.5 mg/ml, eye drops, solution Epinastine hydrochloride Read all of this leaflet carefully before you start using this medicine because it contains important
More informationList of nationally authorised medicinal products
8 March 2018 EMA/182904/2018 Human Medicines Evaluation Division Active substance(s): fluticasone propionate / formoterol fumarate dihydrate Procedure No.: PSUSA/00010339/201707 30 Churchill Place Canary
More informationPublic administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective
Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Prof. Ing. Juraj Nemec, CSc. Masaryk University, Czech Republic, Size of government
More informationList of nationally authorised medicinal products
21 February 2018 EMA/208334/2018 Human Medicines Evaluation Division Active substance: ibuprofen / pseudoephedrine Procedure no.: PSUSA/00001711/201707 30 Churchill Place Canary Wharf London E14 5EU United
More informationList of nationally authorised medicinal products
12 July 2018 EMA/462856/2018 Human Medicines Evaluation Division Active substance: econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide Procedure no.: PSUSA/00001195/201711
More informationTrends in injecting drug use in Europe
Trends in injecting drug use in Europe Linda Montanari, Bruno Guarita and Danica Thanki Annual Expert Meeting on Drug-Related Infectious Diseases Lisbon, 15-17 October Overview of the presentation 1) Information
More informationAnnex I. Article 107i of Directive 2001/83/EC. Procedure number: EMEA/H/A-107i/ March 2013 EMA/147828/2013 Patient Health Protection
07 March 2013 EMA/147828/2013 Patient Health Protection Annex I List of the names, pharmaceutical s, strengths of the medicinal products, routes of, marketing authorisation holders in the member states
More informationFinnish international trade 2017 Figures and diagrams. Finnish Customs Statistics
Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11
More informationFinnish international trade 2017 Figures and diagrams. Finnish Customs Statistics
Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11
More informationImplementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO
Implementation Report on the patient safety Recommendation 2009/C 151/01 Healthcare Systems Unit DG SANCO Published 15 November 2012 REPORT FROM THE COMMISSION TO THE COUNCIL on the basis of Member States'
More informationPalliative nursing care of children and young people across Europe
Palliative nursing care of children and young people across Europe Results of a postal survey in August 2016 Updated in April 2017 (presented at the 29th PNAE-meeting in Naples/Italy on 28th April 2017)
More informationList of nationally authorised medicinal products
1 September 2017 EMA/593212/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): flurbiprofen Procedure No.: PSUSA/00001450/201611 30 Churchill
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Lidocaine Accord 10 mg/ml solution for injection Lidocaine Accord 20 mg/ml solution for injection Lidocaine hydrochloride Read all of this leaflet carefully before
More informationPackage leaflet: Information for the user. LUXFEN, <[2 mg/ml eye drops, solution]> Active substance: brimonidine tartrate
Package leaflet: Information for the user LUXFEN, Active substance: brimonidine tartrate Read all of this leaflet carefully before you start using this medicine because
More informationList of nationally authorised medicinal products
28 September EMA/662335/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): levosalbutamol, salbutamol Procedure No.: PSUSA/00010330/201701 30
More informationEuropean Medicines Agency decision
EMA/357972/2017 European Medicines Agency decision P/0173/2017 of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for colistimethate sodium (Colobreathe), (EMEA-000176-PIP01-07-M05)
More informationTransmission, processing and publication of HBS 2015 data
EUROPEAN COMMISSION EUROSTAT Directorate F: Social statistics Unit F-4: Income and living conditions; Quality of life Doc. LC-ILC/194/17/EN estat.f.4 (2017) WORKING GROUP ON INCOME AND LIVING CONDITIONS
More informationEUROPEAN CITIZENS DIGITAL HEALTH LITERACY
Flash Eurobarometer 404 EUROPEAN CITIZENS DIGITAL HEALTH LITERACY SUMMARY Fieldwork: September 2014 Publication: November 2014 This survey has been requested by the European Commission, Directorate-General
More informationPackage leaflet: Information for the user. Myozyme 50 mg powder for concentrate for solution for infusion Alglucosidase alfa
Package leaflet: Information for the user Myozyme 50 mg powder for concentrate for solution for infusion Alglucosidase alfa Read all of this leaflet carefully before you start using this medicine because
More informationList of nationally authorised medicinal products
30 November 2017 EMA/806830/2017 Human Medicines Evaluation Division Active substance: piroxicam Procedure no.: PSUSA/00002438/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationTadim 1 Million I.E. Pulver zur Herstellung einer Infusionslösung. Tadim 1 Million I.E. Pulver zur Herstellung einer Lösung für einen Vernebler
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration and marketing authorisation s in the member states 1 Austria Forest Pharma B.V. Newtonlaan
More informationRead all of this leaflet carefully before you start using this medicine.
PACKAGE LEAFLET: INFORMATION FOR THE USER Allergo-COMOD nasal spray 20 mg/ml Nasal spray, solution Active ingredient: sodium cromoglicate (Ph. Eur.) 1 spray of 0.14 ml of Allergo-COMOD nasal spray contains
More information'SECTION B EU PARTY. The following abbreviations are used:
'SECTION B EU PARTY The following abbreviations are used: AT Austria BE Belgium BG Bulgaria CY Cyprus CZ Czech Republic DE Germany DK Denmark ES Spain EE Estonia EU European Union, including all its Member
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. NALOXONE 400 microgram/ml solution for injection or infusion. naloxone hydrochloride
PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER NALOXONE 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using
More informationScreening programmes for Hepatitis B/C in Europe
Programme STI, HIV/AIDS and viral hepatitis Screening programmes for Hepatitis B/C in Europe Mika Salminen, Ph.D. European Centre for Disease Prevention and Control Why might screening be needed for hepatitis
More informationMeeting report, September 2005
European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use London, 24 October 2005 Doc. Ref. EMEA//322553/2005 COMMITTEE ON HERBAL MEDICINAL PRODUCTS () Meeting report, 19-20 September
More informationEuropean Medicines Agency decision
EMA/497687/2017 European Medicines Agency decision P/0245/2017 of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for
More information31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million
31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million cancer cases Adult patients (age 15+) 45 major cancer sites
More informationEnsuring protection of public health and patients in member states: priorities, constraints, opportunities
Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Dr. Christa Wirthumer-Hoche AGES Austrian Medicines and Medical Devices Agency Vienna, Austria
More informationProduct name Strength Pharmaceutical form. Flupirtinmaleat AbZ 100 mg Kapseln. Flupirtinmaleat AL 100 mg Hartkapseln. Awegal inject 164,5 mg / 3 ml
Annex I List of the names, pharmaceutical s, strengths of the medicinal products, route of, marketing authorisation s in the Member States 1 Bulgaria Estonia Zentiva k.s. 130 U kabelovn Prague 10237 Czech
More informationREFERENCE GUIDE FOR OPHTHALMIC PREPARATIONS AVAILABLE FOR USE BY ALL OPTOMETRISTS*
APPENDIX III REFERENCE GUIDE FOR OPHTHALMIC PREPARATIONS AVAILABLE FOR USE BY ALL OPTOMETRISTS* *Excluding preparations for use in the treatment of dry eye 1 Antazoline Sulphate (P) For the temporary relief
More informationLIMITE EN COUNCIL OF THE EUROPEAN UNION. Brussels, 7 July /11 LIMITE ENFOPOL 228 DAPIX 81
COUNCIL OF THE EUROPEAN UNION Brussels, 7 July 2011 12390/11 LIMITE ENFOPOL 228 DAPIX 81 NOTE From: Presidency To: Law Enforcement Working Party No. prev. doc.: CM 1508/11 Subject: Results of the questionnaire
More informationPackage leaflet: Information for the user. Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride
Package leaflet: Information for the user Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using this medicine because
More informationPlease note that this draft Annex I will be updated to amend information on concerned products/mahs
22 March 2018 EMA/197481/2018 Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of, applicants, marketing authorisation holders in the member states for for omega-3
More informationList of nationally authorised medicinal products
12 April 2018 EMA/223740/2018 Human Medicines Evaluation Division Active substance: fludarabine Procedure no.: PSUSA/00001406/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationUpdate on public hearing
Update on public hearing PCWP/HCPWP joint meeting Presented by Juan Garcia Burgos on 0 September 017 Head of Public Engagement Department An agency of the European Union A public hearing provides An opportunity
More informationDo not use Allergo-COMOD eye drops - if you are hypersensitive against sodium cromoglicate (Ph. Eur.) or one of the other ingredients.
Allergo-COMOD eye drops 20 mg/ml eye drops Active substance: Sodium cromoglicate (Ph. Eur.) Read all of this leaflet carefully because it contains important information for you. This medicine is available
More informationReview of Member State approaches to the Macrophyte and Phytobenthos Biological Quality Element in lakes
Review of Member State approaches to the Macrophyte and Phytobenthos Biological Quality Element in lakes Report to ECOSTAT Martyn Kelly (Bowburn Consultancy, UK) Sebastian Birk (University of Duisburg-Essen,
More informationPackage leaflet: Information for the user. Rhesonativ 625 IU/ml, solution for injection Human anti-d immunoglobulin
Package leaflet: Information for the user Human anti-d immunoglobulin Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this
More informationEuropean Union herbal monograph on Eschscholzia californica Cham., herba
28 January 2015 EMA/HMPC/680372/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Eschscholzia californica Cham., herba Final Discussion in Working Party on European
More informationEuropean Medicines Agency decision
EMA/38339/2017 European Medicines Agency decision P/0021/2017 of 3 February 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA- 001501-PIP02-13-M02)
More informationEUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008
European Medicines Agency Doc. Ref. EMEA/357907/2008 P/53/2008 EUROPEAN MEDICINES AGENCY DECISION of 20 July 2008 on the application for agreement of a Paediatric Investigation Plan for Atorvastatin calcium
More informationNew trends in harm reduction in Europe: progress made challenges ahead
New trends in harm reduction in Europe: progress made challenges ahead Dagmar Hedrich, Alessandro Pirona, EMCDDA 2 nd European Harm Reduction Conference, 7-9 May 2014, Basel Session 4: Changes in harm
More informationEuropean Union herbal monograph on Glycine max (L.) Merr., lecithinum
31 January 2017 EMA/HMPC/220599/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Glycine max (L.) Merr., lecithinum Final Discussion in Working Party on European Union
More informationEuropean Union herbal monograph on Pistacia lentiscus L., resin (mastix)
7 July 2015 EMA/HMPC/46758/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pistacia lentiscus L., resin (mastix) Draft Discussion in Working Party on European Union
More informationUpdate on EEA s near real time air quality data exchange
Update on EEA s near real time air quality data exchange Jaume Targa (EEA ETC/ACC) Acknowledgement Thanks to all nrt data providers Currently there are 71 providers Latvian Environment, Geology and Name
More information(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Austria Austria Bulgaria Bulgaria
More informationAgencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)
DEPARTAMENTO DE MEDICAMENTOS VETERINARIOS Medicamentos y Productos C/Campezo 1, Edificio 8 28022 Madrid España (Reference Member State) DECENTRALISED PROCEDURE FINAL PUBLICLY AVAILABLE ASSESSMENT REPORT
More informationReport from the CMD(h) meeting held on 17 th and 18 th March 2008
Report from the CMD(h) meeting held on 17 th and 18 th March 2008 CMD(h)/EMEA Sub-Group on Paediatric Regulation Further to the line listings received for authorised medicinal products (including purely
More informationEU Market Situation for Poultry. Committee for the Common Organisation of the Agricultural Markets 20 April 2017
EU Market Situation for Poultry Committee for the Common Organisation of the Agricultural Markets 2 April 217 -9.% -11.% -5.% -.1% -.7% -2.2% 3.% 1.7% 1.2%.8%.6%.%.%.% 7.9% 7.% 6.4% 6.2% 6.% 5.5% 5.3%
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
biosyn Arzneimittel GmbH Schorndorfer Strasse 32, 70734 Fellbach, Germany PACKAGE LEAFLET: INFORMATION FOR THE USER Selenase 100 micrograms, solution for injection (50 micrograms/ml) 100 microgram selenium
More informationExtrapolation and potential impact of IPHS deployment in Europe
SIMPHS2 Validation Workshop Brussels, 31 Jan 2012 1 SIMPHS2 Validation Workshop Extrapolation and potential impact of IPHS deployment in Europe JRC IPTS IS Unit Ioannis Maghiros, Fabienne Abadie, Maria
More informationVARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014
Rose-Marie Molina EMA Infoday London, 14th March 2014 Before 1234/2008 Regulation, variation procedures in the European Union for industry was synonymous of: - Lack of visibility about timelines - Lack
More informationReport. Survey conducted by TNS political & social
Food waste and date marking Survey conducted by TNS political & social This document does not represent the point of view of the European Commission. The interpretations and opinions contained in it are
More informationPackage leaflet: Information for the patient. CINQAERO 10 mg/ml concentrate for solution for infusion reslizumab
Package leaflet: Information for the patient CINQAERO 10 mg/ml concentrate for solution for infusion reslizumab This medicine is subject to additional monitoring. This will allow quick identification of
More informationPackage leaflet: Information for the user. Sevelamer carbonate Zentiva 800 mg film-coated tablets sevelamer carbonate
Package leaflet: Information for the user Sevelamer carbonate Zentiva 800 mg film-coated tablets sevelamer carbonate Read all of this leaflet carefully before you start taking this medicine because it
More information